Global Bone Marrow Transplant Market Overview
Bone Marrow Transplant Market Size was valued at USD 10.8 Billion in 2022. The Bone Marrow Transplant market industry is projected to grow from USD 11.426 Billion in 2023 to USD 17.939 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.80% during the forecast period (2023 - 2032).The increasing prevalence of cancer, lymphoma, and other diseases requiring bone marrow transplant and growing bone marrow transplant research and development activities are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Bone Marrow Transplant Market Trends
- Increasing bone marrow transplant adoption and anemia cases propel market growth.
The increasing bone marrow adoption and anemia cases drive the Market CAGR for adoption. Technological advances further encourage market growth by providing better treatment alternatives. As demand for bone marrow transplants increases, the market's share grows significantly, indicating the increased relevance of such surgeries in treating various medical diseases, including anemia and other associated diseases.
Additionally, the bone marrow transplant market is anticipated to grow due to a significant increase in research and development efforts. This increased emphasis on technological advancement and improving transplantation techniques will accelerate market growth. Researchers and executives are investing in new initiatives to promote the development of more effective and accessible bone marrow transplant treatments. As this upward trend continues, the market predicts a positive impact, including improved outcomes from therapy and the growth of bone marrow transplantation. The increased commitment to research and development indicates the pharmaceutical sector's dedication to addressing growing medical concerns, setting the market for long-term growth.
The growing rate of blood cancer is driving growth in the bone marrow transplantation market. As the prevalence of blood cancer rises, there is an increasing demand for effective treatment options such as bone marrow transplantation. This increased demand drives significant market growth, encouraging healthcare providers and researchers to fulfill the evolving requirements of patients with blood cancer actively. The growing importance of bone marrow transplantation in treating such serious medical illnesses emphasizes its essential role in current medical practices.
For instance, the Health Resources and Services Administration estimates that the donor registry contains more than 9 million potential donors in the U.S. The donor registry comprises approximately 268,000 cord blood units, including over 111,000 units from the National Cord Blood Inventory (NCBI). In 2022, more than 3,000 additional units from NCBI were incorporated. CIBMTR reported that in 2021, 5,073 unrelated and 4,276 related bone marrow and cord blood transplants were conducted in the United States—this rising number of donors is driving the bone marrow transplant market revenue.
Bone Marrow Transplant Market Segment Insights
Bone Marrow Transplant Type Insights
The bone marrow transplant market segmentation, based on type, includes autologous transplant, allogenic transplant, and others. The autologous transplant segment dominated the market, accounting for 60% of market revenue (6.48 Billion). This procedure uses a patient's stem cells for transplantation, demonstrating significant influence and preference in the medical landscape.
Figure 1: Bone Marrow Transplant Market, by Type, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Bone Marrow Transplant Treatment Type Insights
The bone marrow transplant market segmentation is based on treatment type: leukemia, lymphoma, myeloma, myelodysplastic syndrome, myeloproliferative disorders, aplastic anemia, solid tumors, sickle cell anemia, thalassemia, and others. The lymphoma category generated the most income (39.6%). Lymphoma as a major contributor indicates its enormous influence on the demand for marrow transplants. With the rising frequency of lymphoma, the market anticipates an increased need for bone marrow transplantation, a critical therapeutic approach. This trend emphasizes the critical importance of bone marrow transplants in resolving lymphoma-related difficulties, establishing it as a prominent participant in the larger bone marrow transplant industry.
Bone Marrow Transplant End User Insights
The bone marrow transplant market segmentation is based on end users, hospitals, multi-specialty clinics, and ambulatory surgical centers. The hospitals category generated the most income (70%). As primary healthcare providers, hospitals are important in society's acceptance of cell bone marrow operations. Their major engagement highlights hospitals' vital role in providing bone marrow transplants and assuring availability and thorough patient care. The significant proportion hospitals hold demonstrates their importance in shaping and influencing the bone marrow transplant industry dynamics.
Bone Marrow Transplant Regional Insights
By region, the study provides market insights into North America, Europe, Asia-Pacific, and Rest of the World. The North American bone marrow transplant market will dominate this market, owing to advanced medical infrastructure, strong research, and a high prevalence of diseases requiring bone marrow transplants. North America's significant contribution indicates its leading role in driving market dynamics.
Further, the major countries studied in the market report are The US, Canada, Germany, France, the U.K., Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: BONE MARROW TRANSPLANT MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe's bone marrow transplant market accounts for the second-largest market share due to better medical facilities, increased awareness, and a rising number of diseases requiring bone marrow transplants. Further, the German bone marrow transplant market held the largest market share, and the French bone marrow transplant market was the fastest-growing market in the European region.
The Asia-Pacific bone marrow transplant market is expected to grow at the fastest CAGR from 2023 to 2032. This is due to growing healthcare infrastructure, increased awareness, and an upsurge in the prevalence of diseases requiring bone marrow transplantation. Moreover, China’s bone marrow transplant market held the largest market share, and the Indian bone marrow transplant market was the fastest-growing market in the Asia-Pacific region.
Bone Marrow Transplant Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development to expand their product lines, which will help the Bone Marrow Transplant market grow even more. Market participants are also undertaking various strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. The bone marrow transplant industry must offer cost-effective items to expand and survive in a more competitive and rising market climate.
Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the bone marrow transplant industry to benefit clients and increase the market sector. In recent years, the bone marrow transplant industry has offered some of the most significant advantages to medicine. Major players in the bone marrow transplant market, including Lonza, Merck KgaA, Sanofi, AllCells, STEMCELL Technologies Inc., Charles River Laboratories, Beike Biotechnology Co. Ltd., FUJIFILM Cellular Dynamics Inc., CORESTEM, Inc., Gamida Cell, Lifeline Cell Technology, Mesoblast Ltd, PromoCell GmbH, and others, are attempting to increase market demand by investing in research and development operations.
STEMCELL Technologies is a significant manufacturer of high-quality cell culture material, separation technologies, tools, and educational materials worldwide. STEMCELL, which addresses researchers in stem cell, immunology, cancer, regenerative medicine, and cellular treatment, is dedicated to improving people's lives through innovative research and scientific achievements. Demonstrating dedication to diversity and inclusion in STEM, the life sciences sector benefits from their sustainability, community, and social responsibility investments. STEMCELL, as an association of Scientists Supporting Scientists, represents a dedication to positively impacting the world. In January 2024, STEMCELL Technologies announced the acquisition of Propagenix Inc., a biotechnology company headquartered in Maryland. Propagenix was dedicated to developing technologies that facilitated innovative approaches in regenerative medicine.
FUJIFILM Cellular Dynamics, Inc. (FCDI) is a leading producer and manufacturer of human cells for drug discovery, toxicity testing, stem cell banking, and cell therapy research. Collaborating with innovators, the organization readily combines physiologically relevant human cells with cutting-edge technology, driving medical breakthroughs and encouraging better living. FCDI's technique is known for its capacity to create induced pluripotent stem cells (iPSCs) from humans using a routine blood draw and displaying the remarkable ability to develop into practically every kind of cell found in the human body. In November 2023, Century Therapeutics, Inc., and FUJIFILM Cellular Dynamics, Inc. expanded licenses for developing iPSC-derived cell therapies to treat autoimmune and inflammatory diseases, including type 1 diabetes, multiple sclerosis, lupus, and rheumatoid arthritis.
Key Companies in the Bone Marrow Transplant market include
-
Lonza
-
Merck KgaA
-
Sanofi
-
AllCells
-
STEMCELL Technologies Inc.
-
Charles River Laboratories
-
Beike Biotechnology Co. Ltd.
-
FUJIFILM Cellular Dynamics Inc.
-
CORESTEM Inc.
-
Gamida Cell
-
Lifeline Cell Technology
-
Mesoblast Ltd
-
PromoCell GmbH.
Bone Marrow Transplant Industry Developments
September 2023:BioLineRx Ltd. announced FDA approval for APHEXDA™ (motixafortide) with filgrastim for mobilizing hematopoietic stem cells in multiple myeloma patients for autologous transplantation. APHEXDA is administered through subcutaneous injection.
August 2023:Massachusetts General Hospital (MGH) officially inaugurated the Legorreta Center for Clinical Transplant Tolerance, the world's first center to prevent organ rejection post-transplant without requiring lifelong immunosuppressive medications.
September 2021:Sanofi merged with Kadmon Holdings, Inc., adding Rezurock™ (belumosudil) to its transplant portfolio. Rezurock, an FDA-approved treatment for chronic graft-versus-host disease, caters to patients aged 12 and above who have not responded to at least two prior systemic therapies.
Bone Marrow Transplant Market Segmentation
Bone Marrow Transplant Type Outlook
-
Autologous Transplant
-
Allogenic Transplant
-
Others
Bone Marrow Transplant Treatment Type Outlook
Bone Marrow Transplant End User Outlook
Bone Marrow Transplant Regional Outlook
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Rest of Europe
-
Asia-Pacific
-
China
-
Japan
-
India
-
Australia
-
South Korea
-
Australia
-
Rest of Asia-Pacific
-
Rest of the World
-
Middle East
-
Africa
-
Latin America
| Report Attribute/Metric |
Details |
| Market Size 2022 |
USD 10.8 Billion |
| Market Size 2023 |
USD 11.426 Billion |
| Market Size 2032 |
USD 17.939 Billion |
| Compound Annual Growth Rate (CAGR) |
5.80% (2023-2032) |
| Base Year |
2022 |
| Market Forecast Period |
2023-2032 |
| Historical Data |
2018- 2022 |
| Market Forecast Units |
Value (USD Billion) |
| Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
Type, Treatment Type, End User, and Region |
| Geographies Covered |
North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered |
The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled |
Lonza, Merck KgaA, Sanofi, AllCells, STEMCELL Technologies Inc., Charles River Laboratories, Beike Biotechnology Co. Ltd., FUJIFILM Cellular Dynamics Inc., CORESTEM, Inc., Gamida Cell, Lifeline Cell Technology, Mesoblast Ltd, PromoCell GmbH, and others. |
| Key Market Opportunities |
Online platforms offer convenience and wider reach. |
| Key Market Dynamics |
Growing awareness of premium wines and increasing disposable income. |
Frequently Asked Questions (FAQ) :
The bone marrow transplant market size was valued at USD 10.8 Billion in 2022.
The market is projected to grow at a CAGR of 5.80% during the forecast period, 2023-2032.
North America had the largest share of the market
The key players in the market are Lonza, Merck KgaA, Sanofi, AllCells, STEMCELL Technologies Inc., Charles River Laboratories, Beike Biotechnology Co. Ltd., FUJIFILM Cellular Dynamics Inc., CORESTEM, Inc., Gamida Cell, Lifeline Cell Technology, Mesoblast Ltd, PromoCell GmbH, and others.
The autologous transplant category dominated the market in 2022.
The hospitals had the largest share in the market.
